Beijing Hotgen Biotech Co

Beijing Hotgen Biotech Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Beijing Hotgen Biotech Co (688068.SS) as of Nov 5, 2026 is 60.29 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 46.37 % — a change of 30.03% (higher).

FCF Conversion

60.29 %

YoY

30.03%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Beijing Hotgen Biotech Co is 2025 60.29 % . FCF Conversion Rate (FCF/EBITDA) of Beijing Hotgen Biotech Co was 2024 46.37 % . It decreases by 30.03% higher compared to the previous year.

The Beijing Hotgen Biotech Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
27.07 CNY
Jan 1, 2019
-204.00 CNY
Jan 1, 2020
-6.82 CNY
Jan 1, 2021
102.74 CNY
Jan 1, 2022
43.77 CNY
Jan 1, 2023
-1,517.01 CNY
Jan 1, 2024
46.37 CNY
Jan 1, 2025
60.29 CNY
The Beijing Hotgen Biotech Co FCF Conversion history
YEARFCF ConversionYoY
60.29 %+30.03%
46.37 %-103.06%
-1,517.01 %-3,565.61%
43.77 %-57.39%
102.74 %-1,605.88%
-6.82 %-96.66%
-204.00 %-853.50%
27.07 %-117.66%
-153.29 %-281.23%
84.58 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Beijing Hotgen Biotech Co Stock analysis

What does Beijing Hotgen Biotech Co do? Beijing Hotgen Biotech Co., Ltd. generates revenue through the development and manufacturing of in-vitro diagnostic, point-of-care-testing, and biodefense products. The firm's product portfolio primarily consists of in vitro diagnostic reagents, in vitro diagnostic instruments, and biological raw materials. These offerings are designed to address clinical needs in areas such as liver cancer, hepatitis, cardiovascular and cerebrovascular diseases, and inflammatory infections. Additionally, the products serve public safety applications including biosafety, food safety, and disease control and emergency response. The company operates in both domestic and overseas markets, selling its solutions to entities involved in clinical healthcare and public safety sectors. By providing specialized diagnostic tools and biological materials, Beijing Hotgen Biotech Co., Ltd. supports medical diagnosis and emergency response efforts globally. The business model relies on the direct sale of these manufactured goods to customers who require advanced diagnostic capabilities for disease detection and safety monitoring. Beijing Hotgen Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Beijing Hotgen Biotech Co stock

FCF Conversion Rate (FCF/EBITDA) of Beijing Hotgen Biotech Co is 60.29 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Beijing Hotgen Biotech Co changed from 46.37 % to 60.29 %, representing a 30.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Beijing Hotgen Biotech Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Beijing Hotgen Biotech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Beijing Hotgen Biotech Co

All Key Metrics — Beijing Hotgen Biotech Co